The covid vaccine packaging market was valued at USD 3.40 billion in 2025, projected to reach USD 3.57 billion in 2026, and is forecast to expand to USD 5.88 billion by 2036 at a 5.1% CAGR. Ongoing booster vaccination programmes and the establishment of pandemic preparedness stockpiling infrastructure are sustaining demand for pharmaceutical-grade vaccine packaging components. The global vaccine cold chain buildout initiated during the initial pandemic response has created a permanent installed base of ultra-cold storage and transport packaging systems that require recurring replacement and replenishment.
FMI is of the opinion that the covid vaccine packaging market has transitioned from emergency surge procurement into a steady-state replenishment and preparedness category. The initial pandemic period created a one-time capacity expansion across vial manufacturing, syringe filling lines, and cold chain packaging systems. This installed base now generates recurring demand for replacement components, quality upgrades, and stockpile rotation. As per FMI, primary packaging holds 47.0% share as vials, syringes, and stoppers directly contacting vaccine product face the strictest quality and material specifications, commanding the highest unit values. Glass remains the dominant material at 41.0% share, with borosilicate and Valor glass variants gaining share as delamination-resistant and break-resistant alternatives to conventional Type I glass.
All major markets reflect accelerated deployment parameters. India sets a 6.4% CAGR, Germany sets a 5.9% CAGR, Brazil sets a 5.4% CAGR, USA sets a 4.9% CAGR, UK sets a 4.3% CAGR, and Japan sets a 3.8% CAGR. India leads at 6.4% CAGR as its domestic vaccine manufacturing capacity, the largest globally by volume, sustains packaging component procurement. Germany at 5.9% reflects its role as a pharmaceutical glass manufacturing hub. Brazil at 5.4% invests in domestic vaccine packaging capacity to reduce import dependency. The USA at 4.9% maintains steady demand through booster programme logistics and national stockpile rotation. The UK at 4.3% and Japan at 3.8% sustain procurement through their national vaccination programme infrastructure.
| Metric | Details |
|---|---|
| Industry Size (2026) | USD 3.57 billion |
| Industry Value (2036) | USD 5.88 billion |
| CAGR (2026-2036) | 5.1% |
Source: Future Market Insights, 2026
Covid vaccine packaging encompasses pharmaceutical-grade packaging components used in the storage, transport, and administration of covid-19 vaccines. Product categories span primary packaging including vials, syringes, ampoules, and stopper and seal systems that directly contact the vaccine product, secondary packaging such as cartons and boxes for dose grouping and labelling, and tertiary packaging including cold chain shipping containers and temperature-controlled transport systems.
Market scope includes all pharmaceutical-grade packaging components for covid-19 vaccines across primary, secondary, and tertiary packaging levels. Regional and country-level market sizes, forecast period 2026 to 2036, and segment breakdowns by product type, packaging level, and material are fully incorporated.
The scope excludes general pharmaceutical packaging not specific to vaccine applications, non-vaccine cold chain systems, vaccine manufacturing and fill-finish equipment, and vaccine administration devices beyond pre-filled syringes.
The increasing demand for the covid vaccine packaging solutions in a short period has led to a trend among companies in offering pre sterilized primary and secondary packaging solutions.
The pre sterilized secondary packaging solutions like trays, nests and tubs are gaining popularity among the manufacturers. This is mainly because it conveniently eliminates the wash and sterilization process done by the pharmaceutical manufacturing companies and offers them ready to use alternatives for aseptic-fill operations.
There are many companies that are working on developing vaccines with high efficacy and different administration type like oral, intranasal, intramuscular and intradermal. According to the World Health Organization (WHO) data updated on July 6, 2024, there are over 105 vaccines in clinical development and 184 vaccines that are in the pre-clinical development stage.
With the increasing number of vaccines getting approval and development of different vaccine delivery systems the covid vaccine packaging market is anticipated to witness substantial growth during the foreseeable future.
There is alarmingly high demand for the covid vaccine packaging solutions globally. As this level of demand was not anticipated by the manufacturers in the industry the gap between the demand and supply of the packaging solutions is created.
The need for raw materials at a large scale and in a short period was difficult and this created a restraint in the covid vaccine packaging market growth. But with consistent efforts of the manufacturers as well as the government authorities to enhance the manufacturing capabilities, the effect of this restraint is dampening.
The COVID-19 pandemic is still hitting major as well as minor economies of the world severely in the form of second and third waves. Although the effective treatment for the virus is yet to be found, vaccines with higher efficacy are being introduced in the market to tackle the mutated virus.
According to the Our World in Data organization facts updated on July 7, 2024, 24.6% of the total world population has received at least the first dose of vaccine. This creates a huge opportunity for the manufacturers to ramp up their manufacturing capabilities and gain higher market share by preparing themselves to fulfil the upcoming increase in demand.
Key global players such as
In the Asian region, players like
Key players are competing against each other in the industry to acquire maximum market share for multiple segments. In the covid vaccine packaging market, manufacturers are adopting strategies like partnerships and capacity expansions to grow their product offerings and increase the consumer base.
The manufacturers are also focused on making agreements with governments of different countries and international organizations like UNICEF for the supply of covid vaccine packaging solutions.
For instance, in July 2024, Becton, Dickinson and Company signed an agreement with the USA government to provide over 190 million injection devices. Further, the company also received an additional order from the Canadian government for 75 million devices.
Furthermore, in December 2024, Scott AG in its Indian subsidiary Scott Kaisha invested over USD 17 Million for the expansion of its vial manufacturing capacity to reach over 300 million units.
| Metric | Value |
|---|---|
| Quantitative Units | USD 3.57 billion to USD 5.88 billion, at a CAGR of 5.1% |
| Market Definition | Covid vaccine packaging encompasses pharmaceutical-grade primary, secondary, and tertiary packaging components for vaccine storage, transport, and administration, including vials, syringes, closures, cartons, and cold chain transport systems. |
| Product Type Segmentation | Cartons, Ampoules, Syringes, Stoppers and Seals, Vials, Boxes, Others |
| Packaging Level Segmentation | Primary, Secondary, Tertiary |
| Material Segmentation | Glass, Valor Glass, Borosilicate Glass, Plastic, Paper, Metal |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East & Africa |
| Countries Covered | India, Germany, Brazil, USA, UK, Japan, and 40 plus countries |
| Key Companies Profiled | Schott AG, Stevanto Group, Gerresheimer AG, West Pharmaceutical Services Inc., Becton, Dickinson and Company, SGD Pharma, Catalent Inc., B. Braun Melsungen AG, AptarGroup Inc., Cardinal Health Inc., Sealed Air Corporation |
| Forecast Period | 2026 to 2036 |
| Approach | Forecasting models apply a bottom-up methodology starting with global vaccine dose production volumes and per-dose packaging component requirements, cross-validated against packaging manufacturer revenue and stockpile programme procurement data. |
This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with primary research documentation.
How large is the demand for covid vaccine packaging in the global market in 2026?
Demand for covid vaccine packaging in the global market is estimated to be valued at USD 3.57 billion in 2026.
What will be the market size of covid vaccine packaging by 2036?
Market size for covid vaccine packaging is projected to reach USD 5.88 billion by 2036.
What is the expected demand growth between 2026 and 2036?
Demand for covid vaccine packaging is expected to grow at a CAGR of 5.1% between 2026 and 2036.
Which product type is poised to lead global sales by 2026?
Cartons account for 30.0% share in 2026 as the primary secondary packaging format for vaccine dose grouping and cold chain logistics management.
How significant is primary packaging in the covid vaccine packaging market?
Primary packaging holds 47.0% share in 2026 as vials, syringes, and closure systems in direct vaccine contact face the strictest quality specifications and command the highest unit values.
What is driving demand in India?
India's position as the world's largest vaccine manufacturer by volume sustains domestic pharmaceutical-grade packaging component procurement at 6.4% CAGR through 2036.
What is included in the scope of this report?
The market covers all pharmaceutical-grade covid vaccine packaging across primary, secondary, and tertiary levels, with segment breakdowns by product type, packaging level, and material.
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Covid Vaccine Packaging Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
